2013-02-28 07:22:26 -

Tecan Group AG /
Tecan Group AG : Tecan appoints Dr. Stefan Traeger to the Management Board
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Männedorf, Switzerland, February 28, 2013 - The Tecan Group (SIX Swiss Exchange:
TECN) announced today that it has appointed Dr. Stefan Traeger as a member of
the Management Board. As Head of the Life Sciences Business division Stefan
Traeger will be responsible for the Group's global end-customer business. He
will take up his new post at Tecan on July 1, 2013. This position has been
vacant since summer 2012.

Stefan Traeger has extensive domain experience in a variety of management
positions in the life science industry. Since late 2007, he served as Managing
Director of   Leica Microsystems CMS GmbH and as Vice President and General
Manager of Leica's global Life Science Division. Prior to this, Stefan Traeger
held a number of positions with increasing management responsibility in various
areas within the Carl Zeiss Group between 2000 and the end of 2007, most
recently as Director Strategic Business Development of Carl Zeiss Meditec and
Managing Director of Carl Zeiss SMT Ltd.

Tecan CEO David Martyr commented: "During our time together at Leica
Microsystems, I came to know Stefan Traeger as a strong leader who has achieved
significant successes. He resolutely aligned the Life Science division, the
largest division at Leica Microsystems, to the needs of the market, increased
sales considerably and raised profitability significantly. He also very
successfully integrated two acquired companies into the existing business. We
are delighted that Stefan Traeger will now bolster the Tecan management team in
this vital position."

Stefan Traeger holds a PhD from the University of Hannover, Germany, and an MBA
from Purdue University. He is 45 years old and a German citizen.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2011, Tecan generated sales of
CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan
Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss
security number: 1210019).

For further information:
Tecan Group
Martin Brändle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Press Release (PDF): 
 hugin.info/100384/R/1681569/549780.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Tecan Group AG via Thomson Reuters ONE
[HUG#1681569]